JAMA editors call for new FDA monitoring office

Share this article:
The editors of the Journal of the American Medical Association
have used the pages of their publication to call for the independent monitoring of drugs, after they are on the market, by an office separate and independent from the FDA.
"It is unreasonable to expect that the same agency that was responsible for approval of drug licensing and labeling would also be committed to actively seek evidence to prove itself wrong," JAMA editors wrote in their Dec. 1 issue. "One option worth strong consideration...is to establish an independent drug safety board or independent agency for drug safety, specifically to oversee postmarketing surveillance for drugs and devices" The FDA has drawn similar criticism in recent weeks following testimony
on Capitol Hill regarding the withdrawal of Vioxx.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Media

Five things for pharma marketers to know: Wednesday, October 22

Five things for pharma marketers to know: ...

Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.

Mucinex gets a revamp

Mucinex gets a revamp

After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.

Mixed reaction to a health-centric Facebook feature

Mixed reaction to a health-centric Facebook feature

The ACLU is among those questioning the positives of the rumored healthcare effort.